title: Retrograde intra-arterial chemotherapy and daily concurrent proton beam therapy for recurrent oral cavity squamous cell carcinoma: Analysis of therapeutic results in 46 cases.
abstract: The purpose of this study was to evaluate the efficacy and toxicities of proton beam therapy combined with intra-arterial infusion chemotherapy via superficial temporal and occipital arteries for recurrent oral cavity squamous cell carcinoma (SCC).
  
  
  
  Between October 2009 and June 2013, 46 patients with recurrent oral cavity SCC were treated by proton beam therapy combined with intra-arterial infusion chemotherapy of cisplatin (CDDP) and docetaxel. Treatment consisted of proton beam therapy (28.6-74.8 GyE in 13-34 fractions) and intra-arterial infusion chemotherapy (CDDP, 30-50 mg/body/week; docetaxel, 5-25 mg/body/week).
  
  
  
  One-year and 2-year overall survival (OS) rates were 65% and 46%, respectively. One-year and 2-year local control rates were 81% and 70%, respectively.
  
  
  
  These findings suggest that proton beam therapy combined with intra-arterial infusion chemotherapy could be applied effectively and safely for patients with recurrent oral cavity SCC. © 2016 Wiley Periodicals, Inc. Head Neck 38:1145-1151, 2016.
authors.affiliation: Department of Oral and Maxillofacial Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.|Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, Koriyama, Japan.
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Hayashi
authors.affiliation: Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, Koriyama, Japan.
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Nakamura
authors.affiliation: Department of Oral and Maxillofacial Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
authors.forename: Kenji
authors.initials: K
authors.lastname: Mitsudo
authors.affiliation: Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, Koriyama, Japan.
authors.forename: Hisashi
authors.initials: H
authors.lastname: Yamaguchi
authors.affiliation: Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, Koriyama, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Ono
authors.affiliation: Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, Koriyama, Japan.
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Azami
authors.affiliation: Department of Oral and Maxillofacial Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
authors.forename: Kanako
authors.initials: K
authors.lastname: Takayama
authors.affiliation: Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, Koriyama, Japan.
authors.forename: Motohisa
authors.initials: M
authors.lastname: Suzuki
authors.affiliation: Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, Koriyama, Japan.
authors.forename: Yoshiomi
authors.initials: Y
authors.lastname: Hatayama
authors.affiliation: Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, Koriyama, Japan.
authors.forename: Iwao
authors.initials: I
authors.lastname: Tsukiyama
authors.affiliation: Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, Koriyama, Japan.
authors.forename: Masato
authors.initials: M
authors.lastname: Hareyama
authors.affiliation: Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, Koriyama, Japan.
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Kikuchi
authors.affiliation: Department of Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Japan.
authors.forename: Nobukazu
authors.initials: N
authors.lastname: Fuwa
authors.affiliation: Department of Oral and Maxillofacial Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
authors.forename: Iwai
authors.initials: I
authors.lastname: Tohnai
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy; D059186:Chemoradiotherapy, Adjuvant / Q000379:methods*; D002945:Cisplatin / Q000008:administration & dosage; D015331:Cohort Studies; D000072226:Computed Tomography Angiography / Q000379:methods; D018572:Disease-Free Survival; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005260:Female; D006258:Head and Neck Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy; D006801:Humans; D021621:Imaging, Three-Dimensional / Q000379:methods; D007261:Infusions, Intra-Arterial; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy; D009364:Neoplasm Recurrence, Local / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D061766:Proton Therapy / Q000379:methods*; D012189:Retrospective Studies; D018570:Risk Assessment; D000077195:Squamous Cell Carcinoma of Head and Neck; D018709:Statistics, Nonparametric; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin
keywords: intra-arterial chemotherapy; organ preservation; proton beam therapy; recurrent oral cancer; reirradiation